|
|
|
| home > white papers > Clinical Trials in Russia Orange Paper: 1st Quarter 2014 - Synergy Research Group |
|
|
 WHITE PAPERS |
|
Synergy Research Group
|
|
Clinical Trials in Russia Orange Paper: 1st Quarter 2014
|
|
In summary, Russia remains a very popular geography for local, regional,
and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4.
Low cost: Average per patient cost is 60% to 70% below US and European
prices due to the low cost of Investigators and the high concentration
of patients in therapeutically aligned medical centers
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Signant Health finds growing eConsent adoption forecasts and the importance of eClinical integration in latest “State of eConsent” survey
PHILADELPHIA, PA – January 16, 2020: Signant Health, released the
findings from its latest “State of eConsent” report today, highlighting
the sentiments, successes, and challenges of eConsent practitioners
around the world. Join Signant Health’s webinar on February 12, 2020 at
11am ET or 3pm ET to learn more about the findings.
More info >> |
|
 |
White Papers |
 |
|
Spotlight on Quality in Study Startup
Oracle Health Sciences
This white paper addresses the growing interest in quality in clinical trial execution and how workflows play an essential role by building in the steps needed to comply with TMF guidelines, reducing downstream problems. This proactive strategy limits issues caused by siloes, yielding process improvements measurable by performance metrics.
More info >> |
|
 |
Industry Events |
 |
BioTrinity 2020
28-29 April 2020, Etc Venues, London
BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >> |
|
|
|
